| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
83,754,000 |
| Market
Cap: |
1.73(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7.58 - $23.53 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kura Oncology is a clinical-stage biopharmaceutical company engaged in developing medicines for the treatment of cancer. Co.'s primary product candidate, ziftomenib, is a selective, reversible and oral small molecule inhibitor which blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene. Co.'s second product candidate, tipifarnib, is a selective and orally bioavailable inhibitor of farnesyl transferase. Co. is evaluating tipifarnib in multiple solid tumor and hematologic indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
50,000 |
50,000 |
| Total Buy Value |
$0 |
$0 |
$575,000 |
$575,000 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
108,902 |
108,902 |
125,502 |
| Total Sell Value |
$0 |
$2,177,814 |
$2,177,814 |
$2,411,082 |
| Total People Sold |
0 |
5 |
5 |
6 |
| Total Sell Transactions |
0 |
6 |
6 |
11 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hasnain Faheem |
Director |
– • – |
2015-04-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
23,983 |
|
- |
|
| Hoffman Robert |
Director |
– • – |
2015-03-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,494 |
|
- |
|
| Wilson Troy Edward |
President and CEOOfficer |
• • – |
2015-03-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,168,727 |
|
- |
|
| Liu Yi |
Chief Scientific OfficerOffice |
• – – |
2015-03-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
15,624 |
|
- |
|
| Liu Yi |
Chief Scientific OfficerOffice |
• – – |
2015-03-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
734,375 |
|
- |
|
| Gualberto Antonio |
Chief Medical OfficerOfficer |
• – – |
2015-03-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
339,973 |
|
- |
|
| North Annette |
SVP, General CounselOfficer |
• – – |
2015-03-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
93,750 |
|
- |
|
| Ren Pingda |
SVP, ChemistryOfficer |
• – – |
2015-03-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
15,624 |
|
- |
|
| Ren Pingda |
SVP, ChemistryOfficer |
• – – |
2015-03-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
758,358 |
|
- |
|
| Henson Heidi |
Chief Financial OfficerOfficer |
• – – |
2015-03-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,000 |
|
- |
|
| Henson Heidi |
Chief Financial OfficerOfficer |
• – – |
2015-03-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
250,596 |
|
- |
|
| Pappajohn John |
President |
• • • |
2015-03-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,000,000) |
0 |
|
- |
|
| Vassiliou Argyris |
10% Owner |
– – • |
2015-03-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(375,000) |
0 |
|
- |
|
| Vassiliou Argyris |
10% Owner |
– – • |
2015-03-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(625,000) |
0 |
|
- |
|
| Kinley Matthew P |
Secretary, CFO |
• • • |
2015-03-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,000,000) |
0 |
|
- |
|
115 Records found
|
|
Page 5 of 5 |
|
|
0.06 (0.29%) 
